BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15965276)

  • 21. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
    Edelman MJ; Hodgson L; Wang X; Christenson R; Jewell S; Vokes E; Kratzke R
    J Thorac Oncol; 2011 Nov; 6(11):1902-6. PubMed ID: 21964530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
    Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
    Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
    D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
    Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
    De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G
    Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
    Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
    J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
    Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
    J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
    Tissot C; Toffart AC; Villar S; Souquet PJ; Merle P; Moro-Sibilot D; Pérol M; Zavadil J; Brambilla C; Olivier M; Couraud S
    Eur Respir J; 2015 Dec; 46(6):1773-80. PubMed ID: 26493785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
    Orditura M; Romano C; De Vita F; Galizia G; Lieto E; Infusino S; De Cataldis G; Catalano G
    Cancer Immunol Immunother; 2000 Dec; 49(10):530-6. PubMed ID: 11129323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
    Nishio M; Yamanaka T; Matsumoto K; Kimura H; Sakai K; Sakai A; Sone T; Horiike A; Koizumi F; Kasahara K; Ohira T; Ikeda N; Saijo N; Arao T; Nishio K
    J Thorac Oncol; 2011 Nov; 6(11):1889-94. PubMed ID: 21964526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum endostatin levels in patients with lung carcinoma.
    Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
    Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Ossolinska M
    Oncol Res; 2006; 16(1):49-54. PubMed ID: 16783968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum chemokine network correlates with chemotherapy in non-small cell lung cancer.
    Yang D; Zhou J; Zeng T; Yang Z; Wang X; Hu J; Song Y; Chen L; Peer D; Wang X; Bai C
    Cancer Lett; 2015 Aug; 365(1):57-67. PubMed ID: 25976768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.
    Köhler J; Schuler M; Gauler TC; Nöpel-Dünnebacke S; Ahrens M; Hoffmann AC; Kasper S; Nensa F; Gomez B; Hahnemann M; Breitenbuecher F; Cheufou D; Özkan F; Darwiche K; Hoiczyk M; Reis H; Welter S; Eberhardt WE; Eisenacher M; Teschler H; Stamatis G; Schmiegel W; Hahn SA; Baraniskin A
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):795-805. PubMed ID: 26687686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity?
    Zych J; Sakowicz A; Radzikowska E; Załeska J; Rowińska-Zakrzewska E
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():173-8. PubMed ID: 9337535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.
    Kargi A; Bisgin A; Yalcin AD; Kargi AB; Sahin E; Gumuslu S
    Asian Pac J Cancer Prev; 2013; 14(8):4819-22. PubMed ID: 24083751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.